Search the GHTC website

Global health R&D delivers for Nebraska

US government investment in global health R&D has delivered

$7.7 million
to Nebraska research institutions
100+ new jobs
for Nebraska
Global health R&D at work in Nebraska

University of Nebraska Medical Center researchers have used a process called LASER ART (long-acting slow effective release antiretroviral therapy) to extend the action of HIV drugs. By combining LASER ART—a type of injectable drug with an altered chemical structure—with another pharmaceutical agent with no antiviral effect, the scientists showed that the drug composite could reach body tissue conventional drugs cannot. It insulates drug crystals within cells, protecting them from degradation and allowing for the slow release of active ingredients. This breakthrough has the potential to revolutionize HIV therapy. With LASER ART, drug regimens could be transformed from daily burdens to monthly doses, greatly improving patients’ quality of life.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: NIAID/NIH